• Skip to content

Biotech Animated

Biotech Animated | Biotechnology & Life-Science Animation | Beautifully Deliver Your Life-science Company’s Message to a Greater Audience | Biotech Animated is a Life-Science Animation, Advertising Strategy and Business Development Firm

Main navigation

  • Projects
  • About
  • What We Do
  • Our Story
  • Team
  • Join Us
  • Contact Us

Humabodies: Next Generation Drug-conjugates

*Please scroll down to the bottom of the page for the final deliverable.

Project Overview

Crescendo Biologics develops highly differentiated products for cancer therapy using the proprietary Humabody® platform. Humabodies are small, robust protein therapeutics that have fully human VH domains. The origin and size of these Humabodies present distinct advantages over conventional therapeutic antibodies. Crescendo is currently focused on two development programs. These are immuno-oncology modulators and Humabody®-drug conjugates (HDCs).

The objective of this project is to attract the interest of investors, potential partners and potential collaborators. Specifically, video 3 will present Humabody®-drug conjugates (HDCs).

The target audience will have a scientific background and most likely will be working in the Pharmaceutical industry.

Storyboard

crescendo_video_3_17_06-mp4_000008487

With Humabody Drug Conjugates, or HDCs, Crescendo is unlocking the power of antibody drug conjugates.

crescendo_video_3_17_06-mp4_000013994

Carrying just a small amount of highly potent toxin, HDCs are considerably smaller than antibody drug conjugates, or ADCs.

crescendo_video_3_17_06-mp4_000021110

This enables more rapid penetration and accumulation in tumors while also improving clearance from circulation.

crescendo_video_3_17_06-mp4_000031086

Due to their modular structure, multispecific HDC formats have improved specificity for cancer cells by simultaneously binding two or more targets,

crescendo_video_3_17_06-mp4_000036347

and bi- or tri-paratopic formats can dramatically enhance toxin internalization.

crescendo_video_3_17_06-mp4_000041088

This potential for both improved efficacy and reduced toxicity

crescendo_video_3_17_06-mp4_000045927

gives HDCs a superior therapeutic index.

crescendo_video_3_17_06-mp4_000047749

This facilitates a ‘dose high,

crescendo_video_3_17_06-mp4_000050060

hit hard, and leave’ approach,

crescendo_video_3_17_06-mp4_000053547

delivering maximum payload to the tumour

crescendo_video_3_17_06-mp4_000055662

while minimising systemic toxicity.

crescendo_video_3_17_06-mp4_000060565

With HDCs, Crescendo is creating the next generation of drug conjugate therapeutics.

crescendo_video_3_17_06-mp4_000069389

If you are ready to see the data, contact us by emailing info@crescendobiologics.com

Video Final Deliverable

  • Join Us
  • Contact Us

COPYRIGHT © 2023 BIOTECH ANIMATED